Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints
Journal for ImmunoTherapy of Cancer · 2026-08 · 14 (8) · e013976
DOI: 10.1136/jitc-2025-013976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 13.08.2026. Verfasst von Alanis E Rodriguez Rosario und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Puerto Rico School of Medicine, San Juan, Puerto Rico. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Cutaneous Squamous Cell Carcinoma, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, The Nancy L. De Anda Research Foundation.
Abstract (Originalsprache)
Background
Immunotherapeutic approaches for cutaneous squamous cell carcinoma (cSCC) remain limited to programmed cell death protein 1 (PD-1) blockade. Although genomics studies have characterized key driver mutations in cSCC, preclinical models that faithfully recapitulate both the genetic landscape and immune microenvironment of the human disease, that could drive the development of novel, effective therapies, are lacking.
Methods
To address this need, we generated genetically engineered mouse models harboring inducible p53 wmR172H expression and Cdkn2a deletion in stratified epithelia. These mice spontaneously developed well-differentiated and spindle cell cSCCs, whose histopathological and immunological features mimicked those observed in patients. We established syngeneic cell lines and characterized their genomic and transcriptomic profiles through whole exome sequencing and RNA sequencing. We used these syngeneic tumor models to test the effect of STING agonist, PD-1, VISTA and CTLA-4 blockade applied at different schedules and combinations. Finally, immune checkpoint molecules detected in the syngeneic models were validated in human cSCC tissue arrays.
Results
Whole exome sequencing confirmed alterations overlapping with human cSCC, including mutations in Notch , interferon signaling, and cytokine pathways. Transcriptomic analysis revealed the upregulation of immunoregulatory genes, including Cd274 , Lgals9 , and Il33 , suggesting a suppressive tumor immune microenvironment (TIME). Preclinical therapeutic evaluation in this model demonstrated that PD-1 blockade and the treatment with a STING agonist elicited partial responses. The combination of STING agonist with checkpoint inhibition targeting either PD-1/CTLA-4 or PD-1/VISTA significantly enhanced antitumor immunity in tumors resistant to anti-PD-1 monotherapy.
Conclusions
These results establish a robust, genetically defined, immunocompetent platform for modeling cSCC and evaluating novel immunotherapeutic strategies for treating patients with this disease. Our findings also identify VISTA and CTLA-4 as promising immune checkpoints to target in cSCC and support clinical evaluation of this combination of immune checkpoint blockade to overcome immune checkpoint inhibitor resistance and improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
- Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
- Katz Department of Oral and maxillofacial Surgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pathology Anatomical, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA agsikora@mdanderson.org jmyers@mdanderson.org rrangel@mdanderson.org.
Förderung
- NCI NIH HHS
- NIDCR NIH HHS
- The Nancy L. De Anda Research Foundation
- MDACC Institutional Research Grant
- National Institute of Health
- Mary K Chapman Foundation
Zitieren
APA
Rodriguez Rosario, A. E., Rangel, R., Balbin, N., Nizami, Z. N., Hadi, J., Noor, A., Dong, L., Corona, A., Bhavani, N., Cruz Sanchez, R. M., Sunga, G. M., Veeramachaneni, R., Manyam, G. C., Wang, J., Yu, W., Sikora, A. G., N Myers, J., & Rangel, R. (2026). Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints. Journal for ImmunoTherapy of Cancer, 14(8), e013976. https://doi.org/10.1136/jitc-2025-013976
Vancouver
Rodriguez Rosario AE, Rangel R, Balbin N, Nizami ZN, Hadi J, Noor A, et al. Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints. Journal for ImmunoTherapy of Cancer. 2026;14(8):e013976. doi:10.1136/jitc-2025-013976
BibTeX
@article{RodriguezRosario2026,
author = {Rodriguez Rosario, Alanis E and Rangel, Roberto and Balbin, Nicholas and Nizami, Zohra N and Hadi, Jaafar and Noor, Ahmed and Dong, Liping and Corona, Arnoldo and Bhavani, Nikitha and Cruz Sanchez, Ricardo M and Sunga, Gemalene M and Veeramachaneni, Ratna and Manyam, Ganiraju C and Wang, Jing and Yu, Wendong and Sikora, Andrew G and N Myers, Jeffrey and Rangel, Roberto},
title = {Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {8},
pages = {e013976},
doi = {10.1136/jitc-2025-013976}
}
EUVIMED